Prospective efficacy and safety study of neoadjuvant gemcitabine with capecitabine combination chemotherapy for borderline-resectable or unresectable locally advanced pancreatic adenocarcinoma
Jae‐Lyun Lee(Ulsan College), Duck Jong Han(Asan Medical Center), Sung Koo Lee(Ulsan College), Dong Wan Seo(Dankook University), Sang Hyun Shin(Ulsan College), Song Cheol Kim(Ulsan College), Jihoon Kim(University of Tsukuba), Sang Soo Lee(Chungbuk National University Hospital), Jin‐hong Park, Tae‐Won Kim(Ionis Pharmaceuticals (United States)), Do Hyun Park(Massachusetts Institute of Technology), Jong Hoon Kim(Ulsan College), Myung‐Hwan Kim(Korea Aerospace Research Institute)
Cited by 103
Related Papers
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma
|JAMA Oncology|2017|846
Combined circulating tumor DNA and protein biomarker-based liquid biopsy for the earlier detection of pancreatic cancers
|Proceedings of the National Academy of Sciences|2017|577
TIMP-2 Mediated Inhibition of Angiogenesis
|Cell|2003|510